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Deflux Injection for the Treatment of Vesicoureteric
Reflux in Children—A Single Centre’s Experience
Patrick Ho Yu Chung, Lawrence Cheun Leung Lan, Kenneth Kak Yuen Wong and Paul Kwong Hang Tam,
Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Hong Kong.
BACKGROUND: Vesicoureteric reflux (VUR) is a common condition that may lead to end-staged 
renal failure. Treatment options include long term prophylactic antibiotics or surgical intervention.
Recently, endoscopic treatment by a subureteral injection of Deflux has gained popularity. Our centre 
has introduced this treatment modality since 2002.
METHODS: The medical records of 42 patients (15 male and 27 female) who received Deflux injections
for treatment of VUR from 2002 to 2007 were reviewed. All the patients were followed up with voiding
cystourethrograms at 3 months after the procedure.
RESULTS: The median age at operation was 72.59 months (range, 8 to 216 months). Unilateral involve-
ment was found in 20 patients while 22 patients had bilateral involvement. Of the 64 ureters, VUR were
grade II to V in six (9.4%), 31 (48.4%), 20 (31.2%) and seven (10.9%) patients respectively. Resolution of
reflux, defined as grade 0 to I, after one injection was seen in six (100%), 20 (64.5%), and 16 (80%) ureters
from grade II to IV respectively. Only one patient with grade V reflux achieved complete resolution after a
single injection. Of the 21 ureters which had residual reflux, three were lost from follow up and 18 (ten
grade III, two grade IV and six grade V) received a second injection and eventually 12 ureters achieved res-
olution. Thus, the overall success rate was 67.2% after a single injection and 85.9% after two injections.
No procedure-related complications was reported.
CONCLUSION: Injections of Deflux is an effective treatment for VUR. A significant reduction in dis-
ease severity was seen in patients with grade II to IV disease after a single injection. Most patients with
grade V disease needed more than one injection before achieving complete resolution. With this high suc-
cess rate, we recommend the use of endoscopic Deflux injection as the first line treatment for children
with vesicoureteric reflux disease. [Asian J Surg 2009;32(3):163–6]
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Background
Vesicoureteric reflux (VUR) is a common disease encoun-
tered by paediatric surgeons and is seen in 1% to 2% of all
children.1,2 There is a recent increase in detection rate due
to antenatal screening. The most common presenting
symptom is urinary tract infection, which can lead to
renal scarring and subsequent renal failure.2 The poten-
tial mechanism is related to the reflux of infected urine
with interstitial inflammation and renal damage. Sterile
urine can also cause renal damage by mechanical and
immunological mechanisms. Abnormal embryological
development with subsequent renal dysplasia is another
postulation.3
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Current treatment options for this disease include
long term antibiotic prophylaxis to prevent pyelonephritis
and await spontaneous resolution. However, high grade
reflux has a low rate of spontaneous resolution and
patient’s compliance to medication may become a prob-
lem.4,5 The other option will be surgical reimplantation of
ureters, which can be done by either open or laparoscopic
approach. Although it has a high success rate, laparoscopic
approach is invasive and technically demanding.
In recent years, endoscopic injection at the ureteric
opening with bulking agents has gained popularity in the
treatment of VUR. It was first introduced in 1984 on pig
models.6 The principle is to create a solid support behind
the intravesical ureter and elongate the intramural length
of the ureter.7 Various agents, including Teflon, silicon
and bovine collagen have been used and Deflux is one the
most popular substances being currently studied.
Various centres have published results of Deflux injec-
tions over the past few years. Most were able to achieve an
overall success rate of more than 70% with better out-
comes in the low grade group.8–10 Since 2002, our centre
has introduced Deflux injections as the first line of treat-
ment for children with VUR. In this article, we evaluate
our experience of this practice.
Methods
This is a retrospective study from January 2002 to
December 2007. The medical records of all patients who
received Deflux injections for the treatment of VUR dur-
ing the study period were reviewed. The diagnosis and
grading were made based on the findings on voiding 
cystourethrogram.
All injection procedures were done under general anes-
thesia with the patient in cystolithotomy position. A single
dose of intravenous cefuroxamine was given immediately
before operation for prophylaxis. During the operation,
rigid cystoscopy was performed to locate the ureteric ori-
fices. The needle was then introduced via the endoscope
and Deflux was injected into the subureteric space around
the ureteric opening until a volcano appearance was
achieved (Figures 1 and 2). The amount of injection for a
single ureter ranged from 0.5 to 1 ml. All the patients were
followed up with voiding cystourethrogram at 3 months
after the procedure. Antibiotics prophylaxis had been
continued until resolution of reflux was demonstrated in
follow up imaging.
Results
A total of 42 patients (15 male and 27 female) were
included. The median age at operation was 72.6 months
(range, 8 to 216 months). Unilateral involvement was
found in 20 patients while 22 patients had bilateral
involvement. Of the 64 ureters, VUR were grade II to V in
six (9.4%), 31 (48.4%), 20 (31.2%) and seven (10.9%) patients
respectively. Resolution of reflux, defined as grade 0 to I,
after one injection was seen in six (100%), 20 (64.5%), and
16 (80%) ureters from grade II to IV respectively (Table 1).
Only one patient with grade V reflux achieved complete
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Figure 1. The ureteric opening is identified during rigid cysto-
scopy and an injection to the periureteric space.
Figure 2. The injection is completed until a volcano appearance
is seen.
resolution after a single injection. Of the 21 ureters which
had residual reflux, three were lost from follow up and 18
(ten grade III, two grade IV and six grade V) received a sec-
ond injection and eventually 12 ureters achieved resolu-
tion (Table 2). Thus, the overall success rate was 67.2%
after a single injection and 85.9% after two injections. No
procedure-related complications were reported.
Conclusion
Being a common disorder seen in children, much effort
has been placed on the treatment of VUR. Long term
administration of antibiotics as prophylaxis to urinary
tract infection has been advocated previously as the man-
agement option for vesicoureteric reflux disease in chil-
dren. However, prolonged usage of antibiotics is also
associated with bacterial resistance and breakthrough uri-
nary tract infection is not uncommon. Furthermore,
study has shown a low spontaneous resolution rate for
high grade reflux.11
With the advance in surgical endoscopy, cystoscopic
injection of bulking agents has gained popularity.
Compared with long-term antibiotic prophylaxis, this
treatment modality can offer immediate cure with a high
success rate. Yet, it is less invasive and associated with
lesser morbidities compared with ureteric reimplantation
surgery. Since the first experiment of endoscopic injec-
tion in a pig model in 1984, many substances have been
studied with variable results. Polytetrafluoroethylene is
efficacious but associated with distant migration and
granuloma formation.12,13 Silicone also shares the same
problem with marked local inflammatory response.14
The first experimental and short-term results of Deflux
injection were published in 1995 and it has been approved
by the United States Food and Drug Administration since
2001.15 It is a viscous gel consisting of dextranomer
microspheres and stabilised non-animal hyaluronic acid.
Dextranomer microspheres are formed by cross-linking
dextran polymers into porous beads 80–250 μm in diam-
eter. Deflux is non-immunogenic, non-carcinogenic and
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Table 1. Result after single injection
Single injection
Injections count Complete resolution Downgraded No change
# # % # % # %
Grade II 6 6 100.0 0 0.0 0 0.0
Grade III 31 20 64.5 8 25.8 3 9.7
Grade IV 20 16 80.0 1 5.0 3 15.0
Grade V 7 1 14.3 6 85.7 0 0.0
64 43 67.2 15 23.4 6 9.4
Table 2. Result after second injection
First injection Second injection
Injections Complete Lost to Injections Complete 
count resolution follow count resolution
# # % # # # %
Grade II 6 6 100.0 – – – –
Grade III 31 20 64.5 1 10 7 70.0
Grade IV 20 16 80.0 2 2 1 50.0
Grade V 7 1 14.3 0 6 4 66.7
64 43 67.2 3 18 12 66.7
biodegradable. When compared to other bulking agents,
it has a bigger size and therefore migration is less likely 
a problem.16
Regarding the injection technique, many variations
have been described. The degree of hydrodistension,
depth of needle penetration, and amount injected have
been evaluated. However, most centres regard the final
“volcano” appearance, described by P Puri et al,17 as the
predictor of success. An 87% success rate was described 
by Lavelle MT when this morphology was present.
The result from our series was comparable to most 
of the published data in the literature.8–10 We attributed
the slightly lower success rate after a single injection to
the immature technique during the early phase after the
introduction of the technique described by Puri in our
centre. Nevertheless, most patients were able to be cured
after two injections at most. All the patients were followed
up with voiding cystourethrogram at certain time inter-
vals after injection in order to give an objective assessment
of the outcome. Similar to other the published reports18,19
we did not notice any complications associated with the
use of Deflux in our series.
In conclusion, based on our retrospective review,
endoscopic injection of Deflux is a safe and effective man-
agement for paediatric patients with VUR. Even though
there is still no randomised control trial comparing this
with the other treatment modalities, parents should 
be offered this management option during discussion. 
In fact, two surveys of informed parental preference have
also indicated that endoscopic treatment is preferred by
most parents over the other two treatment modalities.20,21
However, they should be warned that a single injection 
is less likely to offer a cure in grade V disease and yet,
repeated injections can still result in high success rates.
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